Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Langerhans cell histiocytosis]

C Thomas1, J Donnadieu, J F Emile

  • 1Service d'hématologie et d'immunologie pédiatrique, hôpital Necker, Paris, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|January 1, 1996
PubMed
Summary

Langerhans cell histiocytosis (LCH) is a rare pediatric disease with varied severity. Optimal treatment strategies are needed for severe LCH cases resistant to chemotherapy, which have a high mortality rate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nemaline rod and central core disease: a coexisting Z-band myopathy.

Muscle & nerve·1997
Same author

Occurrence of myeloproliferative disorder in patients with Noonan syndrome.

The Journal of pediatrics·1997
Same author

Left lateralized P300 amplitude deficit in schizophrenic patients depends on pitch disparity.

Biological psychiatry·1997
Same author

Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease.

Nature medicine·1997
Same author

Lack of expression of E-cadherin is associated with dissemination of Langerhans' cell histiocytosis and poor outcome.

The Journal of pathology·1997
Same author

Diagnosing death. Start resuscitation first.

BMJ (Clinical research ed.)·1997

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Immunology

Context:

  • Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disorder.
  • Incidence is approximately 1 in 200,000 children under 15.
  • LCH presents a broad clinical spectrum, from localized bone lesions to multi-organ system involvement.

Purpose:

  • To highlight the controversial and challenging treatment landscape of LCH.
  • To emphasize the need for improved understanding of LCH pathophysiology.
  • To advocate for prospective, multicenter trials to optimize LCH treatment.

Summary:

  • LCH treatment remains controversial, particularly for multisystemic forms with organ dysfunction.
  • Some severe LCH cases are refractory to current systemic chemotherapy, leading to a high mortality rate (up to 40%).

Related Experiment Videos

  • A deeper understanding of clinical and pathophysiological features is crucial for developing effective therapeutic approaches.

    • Impact:

    • Improved diagnostic and therapeutic strategies for LCH.
    • Enhanced prognosis for patients with severe, unresponsive LCH.
    • Foundation for evidence-based treatment guidelines in pediatric LCH.